Potassium-transporting ATPase subunit alpha gastric-type (ATP4A)

The Potassium-transporting ATPase subunit alpha gastric-type (ATP4A) is the catalytic component of the gastric proton pump, an integral membrane protein responsible for acidifying the stomach contents (UniProt P20648). It functions as a P-type ATPase, utilizing energy from ATP hydrolysis to transport hydrogen ions into the gastric lumen in exchange for potassium ions (NCBI Gene ID: 495). This process represents the final step of gastric acid secretion, making the subunit a critical therapeutic target for acid-related gastrointestinal disorders such as gastroesophageal reflux disease (GERD) and peptic ulcers (StatPearls: Proton Pump Inhibitors). Pharmacological intervention typically involves Proton Pump Inhibitors (PPIs) like omeprazole, which form covalent bonds with cysteine residues on the alpha subunit to irreversibly inhibit its activity (PubMed: 11061577). Newer agents, known as Potassium-Competitive Acid Blockers (PCABs), provide a faster-acting and reversible alternative by competing for the potassium-binding site (PubMed: 29164136). While highly effective, chronic inhibition of this target can lead to clinical concerns such as nutrient malabsorption and altered gut microbiome composition (NIH: LiverTox).

Other names

Gastric H+/K+ ATPase alpha subunitProton pump alpha subunitATP4AH(+)/K(+) ATPase alpha subunit

Inhibition of the gastric H+/K+-ATPase enzyme system. Proton Pump Inhibitors (PPIs) are prodrugs that undergo acid-catalyzed activation to form a tetracyclic sulfenamide, which covalently binds to cysteine residues (notably Cys813) on the alpha subunit, resulting in irreversible inhibition (StatPearls). Potassium-Competitive Acid Blockers (PCABs) inhibit the pump by binding reversibly to the potassium-binding site, blocking the exchange of ions (PubMed: 29164136).